Infectious Disease Hepatitis C Direct Acting Antivirals
31 flashcards covering Infectious Disease Hepatitis C Direct Acting Antivirals for the HEALTHCARE-CE Physician CME section.
Hepatitis C Direct Acting Antivirals (DAAs) are a crucial component of the treatment landscape for chronic Hepatitis C virus (HCV) infection, as defined by the American Association for the Study of Liver Diseases (AASLD) guidelines. These medications work by targeting specific steps in the HCV lifecycle, leading to improved cure rates and reduced side effects compared to previous therapies. Understanding the pharmacology, indications, and patient management strategies associated with DAAs is essential for healthcare professionals involved in treating HCV.
In practice exams and competency assessments, questions about Hepatitis C DAAs often focus on their mechanism of action, drug interactions, and the management of potential side effects. Common traps include confusing the various classes of DAAs and their specific indications, as well as overlooking the importance of patient adherence to the treatment regimen. A frequent oversight among clinicians is not thoroughly assessing patients for potential drug-drug interactions, which can compromise treatment efficacy and patient safety.
Terms (31)
- 01
What is the primary mechanism of action of direct-acting antivirals (DAAs) for Hepatitis C?
DAAs target specific steps in the Hepatitis C virus lifecycle, inhibiting viral replication, which includes protease inhibitors, polymerase inhibitors, and NS5A inhibitors (IDSA Clinical Practice Guidelines).
- 02
What is the recommended duration of treatment with DAAs for most patients with Hepatitis C?
The recommended duration of treatment with DAAs is typically 8 to 12 weeks, depending on the specific regimen and patient factors (IDSA Clinical Practice Guidelines).
- 03
Which direct-acting antiviral is commonly used as a first-line treatment for chronic Hepatitis C?
Sofosbuvir is commonly used as a first-line treatment, often in combination with other agents like ledipasvir or velpatasvir (IDSA Clinical Practice Guidelines).
- 04
What is the significance of achieving a sustained virologic response (SVR) in Hepatitis C treatment?
Achieving SVR, defined as undetectable Hepatitis C RNA 12 weeks post-treatment, indicates a high likelihood of cure and reduced risk of liver-related complications (IDSA Clinical Practice Guidelines).
- 05
What are common side effects associated with direct-acting antivirals for Hepatitis C?
Common side effects include fatigue, headache, nausea, and insomnia, though DAAs are generally well-tolerated (IDSA Clinical Practice Guidelines).
- 06
Under IDSA guidelines, what is required for patients with Hepatitis C before starting DAA therapy?
Patients must undergo a thorough evaluation including HCV genotype testing and assessment of liver fibrosis stage before starting DAA therapy (IDSA Clinical Practice Guidelines).
- 07
What is the role of ribavirin in the treatment of Hepatitis C with DAAs?
Ribavirin may be added to DAA regimens for certain patients with advanced liver disease or those who have failed previous treatments (IDSA Clinical Practice Guidelines).
- 08
When treating Hepatitis C, what should be assessed prior to initiating DAA therapy?
Prior to initiating DAA therapy, assess the patient's liver function, HCV genotype, and any potential drug interactions (IDSA Clinical Practice Guidelines).
- 09
What is the impact of direct-acting antivirals on the transmission of Hepatitis C?
DAAs significantly reduce the viral load, which decreases the risk of transmission to others, particularly in patients who achieve SVR (IDSA Clinical Practice Guidelines).
- 10
Which patient population may require a different DAA regimen due to drug interactions?
Patients on certain medications, such as those with HIV or those taking drugs metabolized by CYP3A4, may require alternative DAA regimens due to potential drug interactions (IDSA Clinical Practice Guidelines).
- 11
What is the recommended follow-up for patients who achieve SVR after Hepatitis C treatment?
Patients who achieve SVR should be monitored for liver health and screening for hepatocellular carcinoma, especially if they have cirrhosis (IDSA Clinical Practice Guidelines).
- 12
How does the presence of cirrhosis affect DAA treatment decisions for Hepatitis C?
Patients with cirrhosis may require longer treatment durations and careful monitoring for side effects and drug interactions when using DAAs (IDSA Clinical Practice Guidelines).
- 13
What is the role of patient education in the management of Hepatitis C with DAAs?
Patient education is crucial for adherence to therapy, understanding potential side effects, and the importance of follow-up testing (IDSA Clinical Practice Guidelines).
- 14
What is the recommended action for patients with Hepatitis C who are co-infected with HIV?
Co-infected patients should receive a DAA regimen that considers drug interactions and may require adjustments based on their HIV treatment (IDSA Clinical Practice Guidelines).
- 15
What is the importance of HCV genotype testing before initiating DAA therapy?
HCV genotype testing is important to determine the most effective DAA regimen and treatment duration for the patient (IDSA Clinical Practice Guidelines).
- 16
What is the significance of baseline HCV RNA levels in treatment planning for Hepatitis C?
Baseline HCV RNA levels help assess the severity of the infection and guide treatment decisions, including the choice of DAA regimen (IDSA Clinical Practice Guidelines).
- 17
What should be monitored in patients receiving DAAs for Hepatitis C during treatment?
Monitor for liver function tests, HCV RNA levels, and any adverse drug reactions throughout the treatment course (IDSA Clinical Practice Guidelines).
- 18
What is the recommended duration of therapy for patients with Hepatitis C genotype 3 using DAAs?
The recommended duration of therapy for patients with Hepatitis C genotype 3 is typically 12 weeks, depending on the specific DAA regimen used (IDSA Clinical Practice Guidelines).
- 19
Which direct-acting antiviral is an NS5A inhibitor used in Hepatitis C treatment?
Ledipasvir is an NS5A inhibitor commonly used in combination with sofosbuvir for treating Hepatitis C (IDSA Clinical Practice Guidelines).
- 20
What is the first step in managing a patient with Hepatitis C who presents with acute liver failure?
The first step is to stabilize the patient and assess the cause of liver failure, including potential Hepatitis C infection, before initiating any antiviral therapy (IDSA Clinical Practice Guidelines).
- 21
What is the recommended management for patients with Hepatitis C who are pregnant?
DAAs are generally not recommended during pregnancy; however, treatment may be considered postpartum (IDSA Clinical Practice Guidelines).
- 22
What is the importance of adherence to DAA therapy in Hepatitis C treatment?
Adherence to DAA therapy is critical for achieving SVR and preventing the development of resistance to antiviral medications (IDSA Clinical Practice Guidelines).
- 23
What are the potential long-term benefits of achieving SVR in Hepatitis C patients?
Achieving SVR can lead to improved liver health, reduced risk of liver cancer, and decreased need for liver transplantation (IDSA Clinical Practice Guidelines).
- 24
What is the role of telemedicine in managing Hepatitis C treatment with DAAs?
Telemedicine can enhance access to care, facilitate monitoring, and improve adherence for patients receiving DAA therapy (IDSA Clinical Practice Guidelines).
- 25
How does the presence of renal impairment affect DAA therapy for Hepatitis C?
Renal impairment may require dosage adjustments or selection of alternative DAAs to prevent toxicity (IDSA Clinical Practice Guidelines).
- 26
What is the recommended screening for Hepatitis C in high-risk populations?
Screening for Hepatitis C is recommended for individuals with risk factors such as injection drug use, HIV infection, and certain medical conditions (USPSTF Recommendations).
- 27
What is the role of combination therapy in treating Hepatitis C with DAAs?
Combination therapy with DAAs enhances efficacy and reduces the risk of developing resistance compared to monotherapy (IDSA Clinical Practice Guidelines).
- 28
What is the significance of drug-drug interactions in patients receiving DAAs for Hepatitis C?
Drug-drug interactions can affect the efficacy and safety of DAAs, necessitating careful medication review and potential adjustments (IDSA Clinical Practice Guidelines).
- 29
What is the recommended follow-up for patients who do not achieve SVR after DAA treatment?
Patients who do not achieve SVR should be evaluated for potential retreatment options and monitored for liver health (IDSA Clinical Practice Guidelines).
- 30
What is the role of patient-reported outcomes in the management of Hepatitis C treatment?
Patient-reported outcomes can provide valuable insights into treatment tolerability, quality of life, and adherence to therapy (IDSA Clinical Practice Guidelines).
- 31
What is the significance of liver biopsy in the management of Hepatitis C?
Liver biopsy may be used to assess the degree of fibrosis and guide treatment decisions, though non-invasive methods are often preferred (IDSA Clinical Practice Guidelines).